Categories: BioTechBuilding
Waypoint's proprietary spatial multi-omics platform enables us to solve critical issues around understanding how cell therapies navigate the three-dimensional tumor microenvironment and allow the measurement of cell-to-cell interactions.
Investors 1
Funding Rounds 1
| Date | Series | Amount | Investors |
| 05.07.2024 | Seed | $14.5M | - |
Mentions in press and media 3
| Date | Title | Description |
| 05.07.2024 | Waypoint Bio (Life Sciences, '21-22) raised $14.5 million in seed funding | - |
| 28.06.2024 | Waypoint Bio Raises $14.5M in Seed Funding | Waypoint Bio Co-founders and CEO Xinchen Wang (L) and Chief Scientific Officer David Phizicky (R) (Photo: Business Wire)
Waypoint Bio, a NYC-based biotechnology company providing novel cell therapies for solid tumors, raised $14.5M in Seed ... |
| - | Waypoint Bio | “Waypoint's proprietary spatial multi-omics platform enables us to solve critical issues around understanding how cell therapies navigate the three-dimensional tumor microenvironment and allow the measurement of cell-to-cell interactions.”... |
Reviews 0
